Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Ev71 Vaccine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07568522CompletedPrimary

Long-Term Immunogenicity of Envacgen® in Children

NCT04072276CompletedPrimary

Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children

NCT02200237Phase 2CompletedPrimary

A Clinical Study for Inactivated Vaccine Against EV71

Showing all 3 trials

Research Network

Common Treatments

  • Ev71 Vaccine2
  • Ev71 With Adjuvant Aluminium Phosphate1

Active Sponsors

  • Medigen Vaccine Biologics Corp.3

Top Investigators

Activity Timeline